



Companies

Licensor
 Licensee

Potential Use

Disease Area
 Indication

Deal Financials

Potential Deal Size
 Upfront
 Milestones Total
 Milestones Regulatory
 Milestones Sales

Research Funding
 Profit Sharing Licensor
 Profit Sharing Licensee
 Royalties
 Equity

Compound

Compound Details
 Compound Name
 Development Stage

Territory
 Year of Deal Establishment
 Free Text Search

Filter Specification

59

OR

No.	Licensor	Potential Deal Size (mln) Amount	Upfront (mln) Remarks	Upfront (mln) Amount	Milestones total (mln) Remarks	Milestones total (mln) Amount	Milestones regulatory (mln)	Milestones regulatory (mln) Amount	Milestones sales (mln) Remarks	Milestones sales (mln) Amount	Research Funding (mln) Remarks	Research Funding (mln) Amount	Profit sharing Remarks	Profit sharing % licensor	Profit sharing % licensee	Rc %
006	Anadys Pharmaceuticals (Scriptgen Pharmaceuticals)	53	including equity	8	-	-	-	-	-	-	-	-	-	0	0	
007	AstraZeneca (MedImmune)	30		10	20		-				0		0	0		
008	AstraZeneca (Novexel)	-		75	- post F II		75				0		0	0		
009	Basilea Pharmaceutica	308		-	-	12 upon EU submission 24 upon FDA		36			0		0	0	0	Do dig